These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 3549399)

  • 21. Gender differences in the reactogenicity of measles-mumps-rubella vaccine.
    Shohat T; Green MS; Nakar O; Ballin A; Duvdevani P; Cohen A; Shohat M
    Isr Med Assoc J; 2000 Mar; 2(3):192-5. PubMed ID: 10774264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination measles, mumps, rubella and varicella vaccine.
    Arbeter AM; Baker L; Starr SE; Levine BL; Books E; Plotkin SA
    Pediatrics; 1986 Oct; 78(4 Pt 2):742-7. PubMed ID: 3763291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serological evaluation of a measles, mumps, and rubella vaccine.
    Robertson CM; Bennett VJ; Jefferson N; Mayon-White RT
    Arch Dis Child; 1988 Jun; 63(6):612-6. PubMed ID: 3291787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The clinico-immunological evaluation of a bivalent vaccine against measles and rubella].
    Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G
    Minerva Pediatr; 1990 Dec; 42(12):531-6. PubMed ID: 2087226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunity against measles and rubella in Massachusetts schoolchildren.
    Orenstein WA; Herrmann K; Albrecht P; Bernier R; Holmgreen P; Bart KJ; Hinman AR
    Dev Biol Stand; 1986; 65():75-83. PubMed ID: 3556779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The immunological efficacy of the combined vaccine Trimovax intended for the prevention of measles, mumps and rubella].
    Samoĭlovich EO; Kapustik LA; Fel'dman EV; Ermolovich MA; Svirchevskaia EIu; Titov LP; Zakharenko DF; Belova EIu; Chernovetskiĭ MA; Korostik TS
    Zh Mikrobiol Epidemiol Immunobiol; 1998; (4):36-40. PubMed ID: 9783398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
    Gerike E; Tischer A
    Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines.
    Weibel RE; Buynak EB; McLean AA; Hilleman MR
    Pediatrics; 1978 Jan; 61(1):5-11. PubMed ID: 263873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination.
    King GE; Markowitz LE; Heath J; Redd SC; Coleman S; Bellini WJ; Sievert A
    JAMA; 1996 Mar; 275(9):704-7. PubMed ID: 8594268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.
    Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL
    Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lidocaine-prilocaine patch decreases the pain associated with the subcutaneous administration of measles-mumps-rubella vaccine but does not adversely affect the antibody response.
    Halperin SA; McGrath P; Smith B; Houston T
    J Pediatr; 2000 Jun; 136(6):789-94. PubMed ID: 10839878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Mumps epidemic in vaccinated children in West Switzerland].
    Ströhle A; Eggenberger K; Steiner CA; Matter L; Germann D
    Schweiz Med Wochenschr; 1997 Jun; 127(26):1124-33. PubMed ID: 9312835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. Should we be concerned?
    Watada B; Kennedy K; Chan D; Church B; Patriquin M; Shariff F; Evans MF
    Can Fam Physician; 1998 Jan; 44():53-5. PubMed ID: 9481462
    [No Abstract]   [Full Text] [Related]  

  • 34. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A; Gerike E
    Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination.
    Lerman SJ; Bollinger M; Brunken JM
    Pediatrics; 1981 Jul; 68(1):18-22. PubMed ID: 7017582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rubini, a new live attenuated mumps vaccine virus strain for human diploid cells.
    Glück R; Hoskins JM; Wegmann A; Just M; Germanier R
    Dev Biol Stand; 1986; 65():29-35. PubMed ID: 3556774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Duration of immunity and occurrence of secondary vaccine failure following vaccination against measles, mumps and rubella].
    Trier H; Rønne T
    Ugeskr Laeger; 1992 Jul; 154(29):2008-13. PubMed ID: 1509566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined trivalent and bivalent measles, mumps and rubella virus vaccination. A controlled trial.
    Swartz TA; Klingberg W; Klingberg MA
    Infection; 1974; 2(3):115-7. PubMed ID: 4606362
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.
    Watson BM; Laufer DS; Kuter BJ; Staehle B; White CJ; Starr SE
    J Infect Dis; 1996 Mar; 173(3):731-4. PubMed ID: 8627041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
    Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
    An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.